Open AccessTeneligliptin versus vildagliptin in Indian patients with type 2 diabetes inadequately controlled with metformin
Author(s) -
Nida Rizvi,
Jameel Ahmad,
Farooq Ahmad,
Sheelu Shafiq Siddiqi
Publication year - 2022
Publication title -
journal of medical pharmaceutical and allied sciences
Language(s) - English
Resource type - Journals
ISSN - 2320-7418
DOI - 10.55522/jmpas.v11i1.1478
Subject(s) - vildagliptin , metformin , postprandial , medicine , tolerability , type 2 diabetes , hypoglycemia , diabetes mellitus , randomized controlled trial , endocrinology , adverse effect
India is heading towards being the diabetes capital of the world indicating that every fifth diabetic in the world is an Indian. The aim to prevent and control diabetic complications can be achieved with a target of glycated haemoglobin (HbA1c) less than 7.0%. There is an urgent need for a cost-effective and safer therapeutic approach for the management of type 2 diabetes. The primary objective was to compare the reduction in fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2-h PPG), and HbA1c, in Group-1and Group-2 at 6, 12, 18 and, 24 weeks with baseline values of two groups. This was a 24-week, randomized, open-label study. Patients with type 2 diabetes who were inadequately controlled on Metformin (850mg, twice a day) were randomized into two groups, Group-1(Metformin 850mg, twice daily added with Vildagliptin 50mg, twice daily) and Group 2(Metformin 850mg, twice daily added with Teneligliptin 20mg, once a day). Reductions in fasting plasma glucose, 2 hours postprandial plasma and HbA1c in the vildagliptin group (Group1) were comparable with the teneligliptin group (Group2). Patients in both groups showed similar tolerability with lesser episodes of hypoglycemia and, are weight neutral. Teneligliptin is noninferior to vildagliptin in controlling glycaemic parameters and shows similar tolerability.